Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Multiomic Profile Integration Reveals Early Signatures of Amyotrophic Lateral Sclerosis and Suggests the MAPK Pathway as a Therapeutic Target

ABSTRACT: Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease and still lacks effective disease-modifying treatments. Here, we performed a multiomic analysis of the prefrontal cortex from 51 sporadic ALS patients and 50 control subjects, as well as from four transgenic mouse models of C9orf72-, SOD1-, TDP-43-, and FUS-ALS to characterize early disease mechanisms in ALS. An integrated analysis of transcriptomes, (phospho-)proteomes, and miRNAomes revealed marked sex-specific differences, more pronounced in males. We identified four transcriptome-based sALS-subclusters that are driven by pathways involved in mitochondrial respiration, synaptic function, immune response and transcription. Diffusion pseudo time estimation suggested that these clusters may represent temporal states in disease progression. Individual omics and multifactorial factor analysis revealed the mitogen-activated protein kinase (MAPK) pathway as a disease-relevant mechanism. Its modulation by trametinib in vitro and in vivo validated MEK2 as an auspicious therapeutic target for a subgroup of ALS patients.

INSTRUMENT(S): Q Exactive HF-X

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Brain

DISEASE(S): Amyotrophic Lateral Sclerosis

SUBMITTER: Marie GEBELIN

LAB HEAD: Christine Carapito

PROVIDER: PXD043297 | Pride | 2024-05-16

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	Mus_pSP_iRT_GM_20200929.fasta	Fasta
	QX16153GM.raw	Raw
	QX16156GM.raw	Raw
	QX16159GM.raw	Raw
	QX16162GM.raw	Raw

Items per page:

1 - 5 of 1106

Similar Datasets

Multiomic Profile Integration Reveals Early Signatures of Amyotrophic Lateral Sclerosis and Suggests the MAPK Pathway as a Therapeutic Target

Project description:Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease and still lacks effective disease-modifying treatments. Here, we performed a multiomic analysis of the prefrontal cortex from 51 sporadic ALS patients and 50 control subjects, as well as from four transgenic mouse models of C9orf72-, SOD1-, TDP-43-, and FUS-ALS to characterize early disease mechanisms in ALS. An integrated analysis of transcriptomes, (phospho-)proteomes, and miRNAomes revealed marked sex-specific differences, more pronounced in males. We identified four transcriptome-based sALS-subclusters that are driven by pathways involved in mitochondrial respiration, synaptic function, immune response and transcription. Diffusion pseudo time estimation suggested that these clusters may represent temporal states in disease progression. Individual omics and multifactorial factor analysis revealed the mitogen-activated protein kinase (MAPK) pathway as a disease-relevant mechanism. Its modulation by trametinib in vitro and in vivo validated MEK2 as an auspicious therapeutic target for a subgroup of ALS patients.

2024-05-16 | PXD043300 | Pride

Multiomic Profile Integration Reveals Early Signatures of Amyotrophic Lateral Sclerosis and Suggests the MAPK Pathway as a Therapeutic Target

2024-05-16 | PXD051889 | Pride

UBQLN2 restrains the domesticated retrotransposon PEG10 to maintain neuronal health in ALS

Project description:Amyotrophic Lateral Sclerosis (ALS) is a rare neurodegenerative disease characterized by motor neuron dysfunction and loss, leading to progressive paralysis and death. A portion of ALS cases is caused by mutation of the proteasome shuttle factor Ubiquilin 2 (UBQLN2), but the molecular pathway leading from UBQLN2 dysfunction to neurodegenerative disease remains unclear. Here, we demonstrate a major function of UBQLN2 in regulating activity of the domesticated gag-pol retrotransposon ‘paternally expressed gene 10’ (PEG10) in human cells and tissues. UBQLN2 exclusively facilitates degradation of the frameshifted gag-pol form of PEG10 through recognition of a unique polyproline repeat. In cells, the PEG10 gag-pol protein cleaves itself in a mechanism reminiscent of retrotransposon self-processing to generate a liberated ‘nucleocapsid’ fragment, which uniquely localizes to the nucleus. Overexpression of the nucleocapsid fragment upregulates transcription of neuronal genes involved in axon remodeling, which were also affected in sporadic ALS (sALS) patient tissues. Finally, proteomics of spinal cords from ALS patients revealed that PEG10 gag-pol is significantly elevated in disease compared to healthy controls. These findings implicate the retrotransposon-like activity of PEG10 as a contributing mechanism in ALS through regulation of neuronal gene expression, and restraint of PEG10 as a primary function of UBQLN2.

2023-03-24 | PXD031964 | Pride

HDAC6 inhibition restores TDP-43 pathology and axonal transport defects in human motor neurons with TARDBP mutations

Project description:TDP-43 is the major component of pathological inclusions in most ALS patients and in up to 50% of patients with frontotemporal dementia (FTD). Heterozygous missense mutations in TARDBP, the gene encoding TDP-43, are one of the common causes of familial ALS. In this study, we investigate TDP-43 protein behavior in induced pluripotent stem cell (iPSC)-derived motor neurons from three ALS patients with different TARDBP mutations and three healthy controls. TARDPB mutations induce several TDP-43 changes in spinal motor neurons, including cytoplasmic mislocalization and accumulation of insoluble TDP-43, C-terminal fragments and phospho-TDP-43. By generating iPSC lines with allele-specific tagging of TDP-43, we find that mutant TDP-43 initiates the observed disease phenotypes and has an altered interactome as indicated by mass spectrometry-based proteomics. Our findings also indicate that TDP-43 proteinopathy results in a defect in mitochondrial transport. Lastly, proteomics analyses also show that pharmacological inhibition of histone deacetylase 6 (HDAC6) restores the observed TDP-43 pathologies and the axonal mitochondrial motility, suggesting that HDAC6 inhibition may be an interesting therapeutic target for neurodegenerative disorders linked to TDP-43 pathology.

2021-03-15 | PXD023852 | Pride

Evaluation of differential gene expression in patients with amyotrophic lateral sclerosis (ALS)

Project description:We compared gene expression profiles of ALS patients with normal patients and with multifocal motor neuropathy (MMN) patients. Skeletal muscle specimens from 3 ALS patients, 3 MMN patients, and 3 control patients were used to find disease markers specifically expressed in ASL and MMN patients.

2011-02-26 | E-GEOD-26276 | biostudies-arrayexpress

Peripheral blood lymphocytes: ALS patients vs. healthy controls

Project description:Transcripional profiling of lymphocytes from patients with amyotrophic lateral sclerosis (ALS) (n=11) and healthy control subjects (n=11). The goal was to determine disease response expression signatures relevant of ALS pathogenesis that affect brain and spinal cord. The reference design was used: each Cy5-labeled cRNA sample from ALS patient or healthy control subject was cohybridized on Agilent-014850 Whole Human Genome Microarray 4x44K G4112F with the reference pool formed with equal amounts of Cy3-labeled cRNAs from each sample from the healthy control group. Eleven lymphocyte samples from definite sporadic ALS patients and eleven samples from healthy control subjects were used.

2011-12-11 | E-GEOD-28253 | biostudies-arrayexpress

Comparative interactome analyses of ALS proteins help define the pathogenic effects of mutant C21ORF2 in motor neurons.

Project description:Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease leading to motor neuron loss. It has a strong genetic contribution, but most ALS-associated gene mutations remain poorly characterized. Therefore, we performed comparative interactome analyses of recently discovered ALS-associated proteins which highlighted many novel binding partners, and both unique and shared interactors. This suggests that different ALS-associated proteins can act through distinct and/or similar cellular pathways. The analysis identified C21ORF2 as a strongly connected protein. The role of C21ORF2 mutations in ALS is largely unknown. Our data show C21ORF2 expression in affected neurons and that the prominent C21ORF2-V58L variant induces apoptosis in mouse neurons and movement defects in zebrafish embryos. iPSC-derived motor neurons from C21ORF2-V58L-ALS patients, but not isogenic controls, show increased apoptosis, and changes in DNA damage response (DDR), mitochondria and electrophysiological properties. In addition, C21ORF2-V58L induced post-transcriptional downregulation of NEK1, an ALS-associated protein implicated in apoptosis and DDR. In all, our data define the pathogenic effects of C21ORF2-V58L and implicate reduced NEK1 levels, due to impaired proteosomal degradation, downstream of this ALS mutation.

2024-09-05 | PXD051922 | Pride

Earliest changes associated with ALS detected in serum EVs.

Project description:Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by the deposition of mutated and misfolded proteins leading to the degradation of motor neurons and the motor cortex. Several ALS-associated proteins have been linked to small extracellular vesicles (EVs). However, the role of these EVs and their cargo in the early stages of ALS has not been investigated. This study aims to identify the earliest protein changes facilitated by EVs in ALS by examining the serum of newly diagnosed ALS patients. EVs were isolated from the serum of ALS (n = 15) and healthy control (HC, n = 15) patients, before undergoing mass spectrometry analysis resulting in the identification of a panel of proteins associated with the early changes of ALS. This panel consists of 9 statistically significantly up-regulated proteins and includes haptoglobin and hemoglobin subunits, complement, and afamin, which are involved in pathways including: heme homeostasis and autophagy. The identification of haptoglobin in the ALS serum EVs suggests it has potential as an early diagnostic biomarker whilst, activation of autophagy pathways suggests early recruitment of clearance pathways in ALS. Therefore, this study uncovers the processes and proteins being facilitated through small EVs in the initial stages of ALS.

2024-03-13 | PXD036652 | Pride

CDK5 and GSK3 mediate neuroinflammation-induced neurodegeneration

Project description:Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by progressive paralysis resulting from specific degeneration of upper and lower motor neurons (MNs). Chronic neuroinflammation, mediated by activated microglia, is a hallmark of patients diagnosed with ALS, and correlates with disease pathogenesis. Protecting MNs, particularly from toxic insults caused by neuroinflammation, could lead to effective treatments of ALS patient. Here, we report a screening campaign identifying a series of pyrazolotriazines that cell-autonomously protect MNs against neuroinflammation. We demonstrate that these compounds inhibit Cyclin-dependent kinase 5 (CDK5) and Glycogen synthase kinase 3 (GSK3), and we use phospho-proteomics to show that neuroprotection is linked to alterations in microtubule dynamics.

2019-01-30 | PXD006452 | Pride

Discovery of biomarkers for amyotrophic lateral sclerosis from human cerebrospinal fluid using mass spectrometry-based proteomics

Project description:Amyotrophic lateral sclerosis (ALS) is progressive neurodegenerative diseases characterized by the relentless loss of upper and lower motor neurons, eventually leading to death. Critical to the mission of developing effective therapies for ALS is the discovery of biomarkers that can illuminate mechanisms of neurodegeneration, as well as that, can be used for diagnostic, prognostic, or pharmacodynamic value across the disease. Here, we merged unbiased discovery-based approaches and targeted quantitative comparative analyses to identify proteins that are altered in cerebrospinal fluid (CSF) from ALS. Mass spectrometry (MS)-based proteomic approaches employing tandem mass tags (TMT) quantification methods from 40 CSF samples comprising 20 patients with ALS and 20 healthy control (HC) individuals identified 53 candidate biomarker proteins after CSF fractionation. Notably, these candidate biomarkers included both previously identified proteins validating our approach and novel ones, expanding the applicability of the biomarkers. Candidate biomarkers were subsequently examined using parallel reaction monitoring (PRM) MS methods on 61 unfractionated CSF samples comprising 30 patients with ALS and 31 HC individuals. Fifteen candidate biomarkers (APOB, APP, CAMK2A, CHI3L1, CHIT1, CLSTN3, ERAP2, FSTL4, GPNMB, JCHAIN, L1CAM, NPTX2, SERPINA1, SERPINA3 and UCHL1) showed significant differences between ALS and Control. Taken together, this study identifies multiple novel proteins that are altered in ALS, which provides the foundation for developing biomarkers for ALS.

2023-05-22 | PXD038846 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data